User:Mr. Ibrahem/Alefacept
| Clinical data | |
|---|---|
| Pronunciation | a lef' a sept |
| Trade names | Amevive |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a603011 |
| Pregnancy category |
|
| Routes of administration | Intravenous, intramuscular |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 63% (IM) |
| Elimination half-life | ~270 hours |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C2306H3594N610O694S26 |
| Molar mass | 51801.25 g·mol−1 |
  (what is this?) (verify) | |
Alefacept, sold under the brand name Amevive, is a medication previously used to treat moderate to severe plaque psoriasis.[1] There are; however, more effective and better tolerated options.[1] It was given by injection into a vein or muscle.[1]
Common side effects included headache, dizziness, nausea, muscle pain, pain at the site of injection, and infection.[1] Other side effects may include low lymphocytes, allergic reactions, and cancer.[1] Safety in pregnancy is unclear.[2] It is a fusion protein which combines part of an antibody with a protein that blocks the growth of some types of T cells.[3][1]
Alefacept was approved for medical use in the United States in 2003.[1] It; however, was withdrawn from the market in 2011.[1]
References[edit]
- ^ a b c d e f g h i j "Alefacept". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 4 November 2021. Retrieved 13 January 2022.
- ^ "Alefacept (Amevive) Use During Pregnancy". Drugs.com. Archived from the original on 3 December 2020. Retrieved 13 January 2022.
- ^ "NCI". www.cancer.gov. 2 February 2011. Archived from the original on 14 January 2022. Retrieved 13 January 2022.